ERBB2 and colorectal carcinoma: HER-2-positive patients with early and advanced stage CRC revealed higher survival rates compared with HER-2-negative cases at three years (86.2 vs. 83.5% and 79.4 vs. 49.1%, respectively) and five years (86.2 vs. 74.3% and 79.4 vs. 40.6%, respectively); however, this difference was also not statistically significant (P=0.328 and P=0.06, respectively; Fig 3).